cagrisema cagrilintide semaglutide phase 3 results 2024 2025 obesity Novo Nordisk's stock drops despite hitting goal of III trial Novo Nordisk has officially filed
Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once weekly injection that combines a GLP 1 receptor agonist with an amylin analogue, setting the stage for the next major We are all anxiously awaiting more research on the combination of cagrilintide and semaglutide (#ozempic #wegovy) which has been shown in global studies to induce very meaningful #weightloss. This study assessed the efficacy Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism
Pay in 4 interest-free payments of $6.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4

